AbbVie
AbbVie and Eisai celebrate approval of new Humira indication
September 28, 2016Research and Development, Sales and Marketing AbbVie, Eisai, Humira
AbbVie and Eisai have announced the Japanese approval of a new indication for the former’s anti-TNF-α monoclonal antibody formulation Humira …
FDA gives the green light to the first Humira biosimilar
September 26, 2016Sales and Marketing AbbVie, Amgen, Amjevita, FDA, Humira
Amgen’s Amjevita has been given the go ahead for all eligible indications of its reference product, including moderate-to-severe rheumatoid arthritis, …
Study shows promise for Venclexta in acute myelogenous leukaemia
August 12, 2016Research and Development, Sales and Marketing AbbVie, Genentech, Roche, Venclexta, venetoclax
A study published in Cancer Discovery, the journal of the American Association for Cancer Research, suggests that Vencletxa (venetoclax) is …
AbbVie files lawsuit against Amgen over Humira copy
August 8, 2016Research and Development, Sales and Marketing AbbVie, Amgen, FDA, Humira, rheumatoid arthritis
Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis …
AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo
July 26, 2016Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t
AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
US FDA committee recommends approval for Amgen’s biosimilar of AbbVie’s Humira
July 13, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, US FDA, biosimilar, drug approval, drug trial, inflammatory diseases, rheumatoid arthritis
One of the world’s bestselling drug may soon have competition in the US markets after the regulators backed a biosimilar …
Amgen’s Humira biosimilar candidate “highly similar” to originator, says FDA
July 8, 2016Research and Development, Sales and Marketing ABP-501, AbbVie, Amgen, FDA, Humira, abp 501, biosimilar
A report from a meeting of the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee has concluded that Amgen’s …
AbbVie’s Imbruvica secures fourth breakthrough therapy designation from US FDA
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AbbVie, US FDA, drug trial, imbruvica
US pharma firm AbbVie (NYSE: ABBV) said the US Food and Drug Administration has granted Imbruvica a fourth breakthrough therapy …
New Humira data shows improved quality of life in ulcerative colitis patients
June 23, 2016Research and Development AbbVie, Humira, data, ulcerative colitis
New data on Humira (adalimumab) has been presented at the British Society of Gastroenterology, demonstrating the drug’s efficacy and improvement …
Nice backs two cancer drugs from Novartis
June 22, 2016Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals
June 15, 2016Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure
Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
EU ombudsman calls for more transparency from AbbVie on Humira
June 10, 2016Medical Communications, Research and Development AbbVie, EMA, EU, Humira, ombudsman
Abbvie continues to withhold details of clinical trials involving the world’s top-selling prescription medicine, Humira (adalimumab), according to the European …
AbbVie says Stemcentrx’ lung cancer drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
AbbVie says Stemcentrx’ stem cell drug shows some benefits in early trials
June 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AbbVie, Stemcentrx, drug trial, lung cancer, rova-t
US drug firm AbbVie (NYSE: ABBV) said its early-stage trials for its drug to treat an aggressive form of lung …
AbbVie, Janssen’s Imbruvica gets European approval to teat CLL
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, CLL, drug trial, regulation
AbbVie (NYSE: ABBV) on Tuesday said Imbruvica (ibrutinib) has secured European regulatory backing to treat chronic lymphocytic leukemia or CLL. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
